Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant and left ventricular mass in abdominal adiposity
2007-001787-71Phase 4Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Abdominal adiposity (ABCD), left ventricular hypertrophy (LVH) and heart failure (HF) comparing Rimonabant with Placebo (2 arms). Primary endpoint: Absolute change of left ventricular mass at 36 weeks. Started Dec 2007; status: terminated.
02
Drugs
rimonabant
03
Conditions
Abdominal adiposity (ABCD)left ventricular hypertrophy (LVH)heart failure (HF)
Beyond the preview
Go deeper on 2007-001787-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001787-71.